SCHEMBL3074056

SCHEMBL3074056

NC(=NOCC(CN1CCCCC1)OC(=O)c1ccccc1)c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
ALDH1A1 P00352 3/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 3/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DRD4 P21917 1/20 0.41
SLC6A2 P23975 1/20 0.41
CCKAR P32238 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
SCN1A P35498 1/20 0.41
OPRK1 P41145 1/20 0.41
HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3070319 0.90 ALDH1A1 (0.43) LMNAALDH1A1KDM4EMAPTKMT2A
Hydrochloric Acid SCHEMBL3070494 0.89 RAB9A (0.56) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3069773 0.89 MEN1 (0.43) LMNAALDH1A1KMT2AMEN1DRD4
SCHEMBL3069776 0.89 MEN1 (0.43) LMNAALDH1A1KMT2AMEN1DRD4
SCHEMBL3066151 0.88 KMT2A (0.57) LMNAALDH1A1HTTKDM4EKMT2A
SCHEMBL3074128 0.87 ALDH1A1 (0.41) LMNAALDH1A1HTTKMT2AMEN1
Hydrochloric Acid SCHEMBL3065835 0.86 TBXA2R (0.43) LMNAALDH1A1KDM4EMAPTKMT2A
SCHEMBL5698982 0.83 GAA (0.47) LMNAALDH1A1HTTKDM4EMAPT
Hydrochloric Acid SCHEMBL3066123 0.82 GAA (0.48) LMNAALDH1A1HTTKDM4EMAPT
Bgp-15 SCHEMBL3073374 0.81 HSF1 (0.46) LMNAALDH1A1DRD4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966283-B1 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING DISEASES RESULTING FROM THE DAMAGING OF THE VASCULAR ENDOTHELIAL CELLS CYTRX CORP (US) 2006-06-14 EP claimed
US-6143741-A TREATING OR PREVENTING ILLNESSES RESULTING FROM DAMAGED ENDOTHELIAL CELLS SUCH AS ATHEROSCLEROSIS, THROMBOSIS, RESTENOSIS, VESSEL SPASM BY ADMINISTERING HYDROXYLAMINE DERIVATIVE BIOREX Kutato es Fejleszo Rt. (HU) 2000-11-07 US claimed
EP-0966283-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX RT. (HU) 1999-12-29 EP claimed
WO-1998006400-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) 1998-02-19 WO claimed
US-20100267711-A1 METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF CYTRX CORPORATION (US) 2010-10-21 US disclosed
US-7745465-B2 Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof CYTRX CORPORATION (US) 2010-06-29 US disclosed
US-7148239-B2 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof CYTRX CORPORATION (US) 2006-12-12 US disclosed
EP-0966283-B1 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING DISEASES RESULTING FROM THE DAMAGING OF THE VASCULAR ENDOTHELIAL CELLS CYTRX CORP (US) 2006-06-14 EP disclosed
US-20040067940-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof BIOREX RESEARCH & DEVELOPMENT CO. 2004-04-08 US disclosed
US-20040019103-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof BIOREX RESEARCH & DEVELOPMENT CO. 2004-01-29 US disclosed
US-6653326-B1 For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders BIOREX RESEARCH & DEVELOPMENT CO. (HU) 2003-11-25 US disclosed
EP-0801649-B1 HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF BIOREX KUTATO FEJLESZTOE KFT (HU) 2002-08-07 EP disclosed
US-6143741-A TREATING OR PREVENTING ILLNESSES RESULTING FROM DAMAGED ENDOTHELIAL CELLS SUCH AS ATHEROSCLEROSIS, THROMBOSIS, RESTENOSIS, VESSEL SPASM BY ADMINISTERING HYDROXYLAMINE DERIVATIVE BIOREX Kutato es Fejleszo Rt. (HU) 2000-11-07 US disclosed
EP-0966283-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX RT. (HU) 1999-12-29 EP disclosed
WO-1998006400-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) 1998-02-19 WO disclosed
EP-0801649-A2 HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF BIOREX KUTATO ES FEJLESZTÖ RT. (HU) 1997-10-22 EP disclosed
WO-1997016439-A1 HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF Biorex Kutató és Fejlesztó Rt. (HU) 1997-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267711-A1 METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF HSPE1, HSF1, HSP90AB2P LMNA 3706/4885ALDH1A1 533/4885HTT 55/4885
US-20040019103-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof HSPE1, HSF1, HSPA1A LMNA 3687/4885ALDH1A1 641/4885HTT 46/4885
US-20040067940-A1 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof HSPE1, HSF1, HSPA1A LMNA 3687/4885ALDH1A1 641/4885HTT 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.